The question was: In early breast cancer, could we select an at-risk population and show that adding [a CDK inhibitor] for 2 years in addition to their endocrine therapy would [reduce the rate of] early recurrences in the f irst 2 to 3 years? Please speak on how t...
is approved for use as a monotherapy in the advanced setting and in combination with endocrine therapy in the advanced setting as well as in high-risk early-stage breast cancer.
Abemaciclib, reported to be a selective CDK4/6 inhibitor40, is a third generation CDK-directed drug with an impressive clinical performance in the treatment of HR+ metastatic breast cancer41,42,43. However, it has been suggested early on that abemaciclib may exhibit pan-selective kinase ...
In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer. Listen Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss ...
Background/Aim: Abemaciclib is a cyclin-dependent kinase 4/6 inhibitor approved in combination with endocrine therapy for treating hormone receptor-positive and human epidermal growth factor receptor 2-negative early and advanced breast cancer patients. The safety profile of abemaciclib is characterized ...
[188]. A Phase I clinical trial with abemaciclib has performed to evaluate itsantitumor activity,pharmacokinetics,pharmacodynamics, and safety profile [189,190]. Early clinical activity has investigated in patients with metastatic human breast cancer,NSCLC,ovarian cancer, andmelanoma[189]. Abemaciclib ...
Cytotoxic chemotherapy is often initiated early in the course of HR+, HER2- advanced breast cancer despite absence of visceral crises, potentially denying patients effective and tolerable standard-of-care regimens containing ET. The current study, known as 13Y-MC-JP...
Table 2. No independent clinico-pathological predictors of meeting eligibility for abemaciclib in 139 women with grade 1–2, hormone-positive, HER2−negative, early breast cancer and <50 mm tumour diameter, undergoing cANC following SNB showing 1–3 nodes with metastatic deposits. 4. Discussion...
Breast cancer is the leading cancer diagnosed in women globally and the second most common cause of cancer-related death in women, following lung cancer [1]. Hormone receptors (HRs) are expressed in about 70% of breast cancer cases, with early-stage diagnosis being more frequent than metastatic...